Xia T, Brucker AJ, McGeehan B, et al. - In this retrospective cohort study, experts aspired to explore whether checkpoint inhibitors (CPIs) confer an increased risk of non-infectious uveitis or myasthenia gravis (MG) compared with patients on non-checkpoint inhibitor (N-CPI) chemotherapy. Eligibility was given to all patients who had started CPI (ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, cemiplimab and durvalumab). Compared with N-CPI chemotherapy, exposure to CPI confers a higher risk for non-infectious uveitis and MG.